BIOCORAL RECEIVES FRENCH PATENT APPROVAL.
INPI, after a lengthy examination of the company's application, granted the patent innovation which is valid for 20 years from the date of application in 1997.
Biocoral, a natural coral derived bone graft substitute, is widely used by numerous surgeons and practitioners because of its biocompatibility, resorbability, Osseo conduction and safety. These accredited qualities will be highly enhanced by a newly developed tissue engineering technique which deals with mesenchymal cells. These cells are obtained from a superficial biopsy excised from the patient, and are in vitro introduced by means of a bone promoter into bone cells and directly in the core of a Biocoral block, giving rise to a hybrid bone auto graft, i.e., Coral Block-Bone Cells.
Nasser Nassiri, the chairman and CEO of Biocoral, Inc. commented, "The long collaboration for the last few years between the high tech company Biocoral, Inc. and accredited institutional Scientifics and researchers has resulted in an international new patent application which has now been granted in France. The company believes that in the near future this new patent will receive approval in other European countries as well as in North America where the patent application has been filed and is already pending."
In addition, the range of clinical application is wide open to the field of bone regeneration (orthopaedics, oral and maxillo facial surgery) and, in particular, osteoporosis where the company has developed and owns several patents.
The company, together with its wholly owned subsidiaries, owns various patents on its technologies most of which have been granted and issued in the United States by the U.S Department of Commerce Patent and Trademark Office, and in Canada, Australia, Japan, the European community and various other countries through their official governmental patent offices.
Biocoral, Inc., a Delaware corporation, is an international biomaterials "tissue-engineering" company specializing in the research and development of proprietary health care patented high technology and biomaterials. Through its subsidiaries, the company researches, develops, manufactures and commercialize bone graft substitutes and other high tech patented biomaterials in a number of countries outside the United States.
For more information, call 011-331-47 57 98 43
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 1, 2001|
|Previous Article:||DECODE SELECTS MILLIPORE MULTISCREEN PURIFICATION PLATFORM.|
|Next Article:||RADIANCE BEGINS BETA RADIATION STUDY IN PERIPHERAL VESSELS.|